A Journey Into Participation Patterns Among Metastatic Prostate Cancer Patients
NCT ID: NCT06009549
Last Updated: 2023-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
500 participants
OBSERVATIONAL
2024-09-30
2026-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This research will admit a wide range of data on the clinical study experience of metastatic prostate cancer patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.
It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future patients with metastatic prostate cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients
NCT06070272
Analyzing Clinical Trial Experiences of Prostate Cancer Patients
NCT05411354
EMPOWER Men to Reduce Weight and Inhibit Prostate Cancer Progression
NCT04266431
Exercise for Advanced Prostate Cancer: a Multicomponent Feasibility Trial
NCT03658486
A Study to Describe Patterns of Care and Outcomes of Men Who Are at High Risk After Experiencing Biochemical Failure Following Definitive Prostate Cancer Therapy, Men With Castration-resistant Prostate Cancer and Men With Metastatic Prostate Cancer
NCT02066961
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of metastatic prostate cancer
* Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria
* Patients with psychiatric illness/social situations that would limit compliance with study requirements
* Inability to provide written informed consent
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Power Life Sciences Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Michael B Gill
Role: STUDY_DIRECTOR
Power Life Sciences Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Power Life Sciences
San Francisco, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Pouliot F, Beauregard JM, Saad F, Trudel D, Richard PO, Turcotte E, Rousseau E, Probst S, Kassouf W, Anidjar M, Camirand Lemyre F, Bouvet GF, Neveu B, Tetu A, Guerin B. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. BJU Int. 2022 Sep;130(3):314-322. doi: 10.1111/bju.15621. Epub 2021 Nov 11.
Vlaming M, Bleiker EMA, van Oort IM, Kiemeney LALM, Ausems MGEM. Mainstream germline genetic testing in men with metastatic prostate cancer: design and protocol for a multicenter observational study. BMC Cancer. 2022 Dec 30;22(1):1365. doi: 10.1186/s12885-022-10429-2.
Presti J Jr, Alexeeff S, Horton B, Prausnitz S, Avins AL. Changes in Prostate Cancer Presentation Following the 2012 USPSTF Screening Statement: Observational Study in a Multispecialty Group Practice. J Gen Intern Med. 2020 May;35(5):1368-1374. doi: 10.1007/s11606-019-05561-y. Epub 2019 Dec 9.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
88079658
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.